Astrid Blom

Astrid Blom

Auto-generated profile, based on publicly available information

Astrid Blom

Department of General and Oncologic Dermatology, Ambroise-Paré Hospital, CARADERM Network, Boulogne-Billancourt, France; Research unit EA 4340, University of Versailles-Saint-Quentin-en-Yvelines, Paris-Saclay University, Boulogne-Billancourt, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
TKThibault Kervarrec
Thibault Kervarrec
SASilke Appenzeller
Silke Appenzeller
MSMahtab Samimi
Mahtab Samimi
BSBhavishya Sarma
Bhavishya Sarma
ESEva-Maria Sarosi
Eva-Maria Sarosi
DSDavid Schrama
David Schrama

23 November 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
RMR. Molinier
R. Molinier
ARAnissa Roger
Anissa Roger
BGB. Genet
B. Genet
ABA. Blom
A. Blom
CLC. Longvert
C. Longvert
EFElisa Funck-Brentano
Elisa Funck-Brentano
The COVID-19 pandemic has had a profound impact on the healthcare system worldwide, which led to a decrease in the number of melanoma diagnosis,1 but the consequences of lockdown on newly diagnosed melanomas severity have not been widely reported. We aimed to evaluate how the first lockdown in France impacted the incidence and prognostic characteristics of new melanomas, in our skin cancer center in the Parisian region, highly affected by the pandemic.

28 September 2021 in International Journal of Women's Dermatology
Verified
Journal Article
Open access
SDSolène Huynh Dagher
Solène Huynh Dagher
ABAstrid Blom
Astrid Blom
HCHedi Chabanol
Hedi Chabanol
EFElisa Funck-Brentano
Elisa Funck-Brentano
• Cutaneous toxicities are frequent with targeted therapies. • Managing cutaneous toxicities is critical for life-saving treatment continuation. • Dermatologists can provide a key input in preventing and managing these toxicities.

8 April 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
MDMarie-Alice Durand
Marie-Alice Durand
ADAurélie Drouin
Aurélie Drouin
AMAlice Mouchard
Alice Mouchard
LDLaurine Durand
Laurine Durand
CEClara Esnault
Clara Esnault
TKThibault Kervarrec
Thibault Kervarrec

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ARAnissa Roger
Anissa Roger
AFAdeline Finet
Adeline Finet
BBBlandine Boru
Blandine Boru
JMJean-Jacques Mazeron
Jean-Jacques Mazeron
YOYves Otmezguine
Yves Otmezguine
PSPhilippe Saiag
Philippe Saiag
E21008 Background: Information on the role and type of radiotherapy in melanoma pts treated with anti-PD1 is limited. We report a cohort of advanced melanoma pts having received simultaneous hypofractionated radiotherapy and anti-PD-1 monotherapy. Methods: Database search in the prospective database of a referral center with standardized radiotherapy procedures for all pts having received both treatments between 1/1/15-30/6/16. Radiologists performed independent tumor evaluations (RECIST 1.1) every 3 m, both on radiated and non-radiated lesions. Results: 25 pts with inoperable AJCC stage 3-4 melanoma, mean age 60.5 Y. Anti-PD-1 monotherapy was first systemic treatment in only 40% of pts. Median follow-up after onset of anti-PD-1 therapy (83% nivolumab, 17% pembrolizumab) was 13.3 m, with 48% of pts still alive at last follow-up. Radiotherapy was performed either early (within first 3 m of PD-1 blockade) in pts with rapidly progressing symptomatic lesion(s) (60% of pts) or late ( > 3 m) in pts with slow progression or dissociated response (40% of pts). It consisted of 1 weekly radiation during 4-5 w (84% of pts), or 1 gammaknife radiation for cerebral mets (16% of pts). Median delay between onset of PD-1 blockade and radiotherapy was 1.8 m (range 0.5-11 m). For radiated lesions, rates of complete (CR), partial (PR) responses, stabilization (S) or progression (P) were 24%, 8%, 44%, and 28%, respectively. For non-radiated lesions (84% of pts), rates of CR, PR, S, and P were 29%, 19%, 19%, and 33%, respectively. Among pts radiated late for insufficient response to anti-PD-1 monotherapy, CR or PR in non-radiated lesions (i.e. abscopal response) was observed in 56% of pts. Anti-PD-1 therapy could be discontinued in 4 pts with CR, without relapse to date. No unusual adverse event was recorded. Conclusions: Hypofractionated radiotherapy may enhance anti-PD1 monotherapy efficacy in difficult-to-treat pts. Controlled studies are needed.